Inscripta plans to expand the capabilities of its Onyx™ Digital Genome Engineering platform beyond microbes, to include the ability to support mammalian cells including humans, CEO Kevin Ness tells GEN Edge . . .
With $125M More in Financing, Inscripta Ramps Up Expansion
Benchtop Genome Editing System Developer Eyes Mammalian Cell Support, Combinatorial Editing Product
Inscripta Kevin Ness, PhD, says his company’s recently-launched Onyx™ Digital Genome Engineering platform aims to help researchers unlock the potential of CRISPR beyond simply editing a gene. Inscripta this month completed a $125 million Series D financing. [Inscripta via Twitter]
